Mass spectrometry methods for detecting monoclonal immunoglobulins in multiple myeloma minimal residual disease

Seminars in Hematology
Katie L Thoren

Abstract

Mass spectrometry methods that can detect low levels of monoclonal immunoglobulin in serum have recently been developed. These assays are based on the principle that each immunoglobulin has a unique amino acid sequence and therefore, has a unique mass. This mass can be used as a surrogate marker in order to monitor a patient's disease over time and at low levels. Here, we explain these methods, discuss their advantages and disadvantages and how they may be used to monitor monoclonal immunoglobulins for minimal residual disease detection in multiple myeloma.

Citations

Jan 24, 2019·Current Hematologic Malignancy Reports·Shalin KothariSarah A Holstein
Aug 1, 2019·British Journal of Haematology·Susan BalLuciano J Costa
Jul 31, 2018·Expert Review of Proteomics·Viviana GrecoAndrea Urbani
Feb 23, 2020·Frontiers in Oncology·Stefania OlivaAlessandra Larocca
Oct 27, 2018·Nature Reviews. Disease Primers·Giampaolo MerliniMorie A Gertz
Dec 19, 2020·Communications Biology·Claudia Tapia-AlvealTilla S Worgall
Jan 1, 2020·Expert Review of Precision Medicine and Drug Development·Matthew HoKenneth C Anderson
Jul 3, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mariya LiyasovaSuzanne Trudel
Jul 30, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kenneth C AndersonShaji K Kumar

❮ Previous
Next ❯

Related Concepts

Related Feeds